Citizens Reiterates Market Outperform on Opus Genetics, Maintains $17 Price Target

Citizens analyst Jonathan Wolleben has reiterated a Market Outperform rating for Opus Genetics (NASDAQ: IRD) and has maintained a price target of $17 for the stock.